|Videos|June 3, 2020

John Strotbeck: How Boathouse Sports Started Making PPE

John Strotbeck, Olympian and CEO of Boathouse Sports, explains how and why the outerwear company pivoted to PPE production at the start of the COVID-19 pandemic.

Segment Description: John Strotbeck, Olympian and CEO of Boathouse Sports, explains how and why the outerwear company pivoted to PPE production at the start of the COVID-19 pandemic.

Previous Coverage: Strategic National Stockpile: Supplies Fail to Go Where Needed Most

PPE is a term that nearly everyone is familiar with now due to the SARS-CoV-2 pandemic. Currently, international shortages of PPE have been plaguing health care workers and hospitals.

Mask shortages were noted in February, with a considerable amount of manufacturing issues due the pandemic coupled with stockpiling and rapid efforts to prepare. From surgical masks to N95 respirators, such PPE has become the new gold to acquire. With such shortages noted and an increasingly strained US health care infrastructure working to combat the threat of COVID-19, the Strategic National Stockpile (SNS) was put into place.

The SNS is designed to provide critical supplies including medical counter measures, but also PPE and medical equipment, to help supplement those states struggling to keep up. Kept in storage, the SNS supplies are deployed “If a community experiences a large-scale public health incident in which the disease or agent is unknown, the first line of support from the stockpile is to send a broad-range of pharmaceuticals and medical supplies. Contents are pre-packed and configured in transport-ready containers for rapid delivery anywhere in the United States within 12 hours of the federal decision to deploy. Each package contains 50 tons of emergency medical resources.”

Within the SNS there are several branches that range from information and planning to operational logistics and science. Medical and pharmaceutical products are just 1 piece of the SNS, with PPE and medical equipment also making up inventory.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.